nach oben

Erschienen in:

07.06.2018 | Original Research

Effect of Continuous Intravenous Calcium Loading on Fibroblast Growth Factor 23 in Normal and Uremic Rats

verfasst von: Yasuto Shikida, Masahide Mizobuchi, Takashi Inoue, Toma Hamada, Hiroaki Ogata, Fumihiko Koiwa, Takanori Shibata

Erschienen in: Calcified Tissue International | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Fibroblast growth factor 23 (FGF23) is associated with mortality in patients with CKD. However, the mechanisms underlying stimulation of FGF23 remain to be investigated. We examined whether hypercalcemia induced by continuous intravenous (CIV) calcium (Ca) infusion regulates FGF23 levels in normal rats (Normal) and 5/6 nephrectomized uremic rats (Nx). Microinfusion pumps were implanted in the Normal and Nx rats for CIV Ca infusion, and blood, urine, kidney, and tibia were collected. The results showed an increase in serum Ca-stimulated FGF23 independently of serum phosphate (P) and creatinine levels in Normal and Nx rats. FGF23 mRNA from the tibia was also increased by the Ca infusion. Despite high FGF23 levels after Ca infusion, urinary P excretion was decreased. Renal α-Klotho expression was significantly reduced by Ca infusion. These results suggest that intravenous Ca loading might stimulate FGF23 production from bone in normal and uremic rats. Reduction of renal P excretion suggests that the bioactivity of FGF23 is inhibited, and the decrease in renal α-Klotho expression might have a role in this pathological process. In conclusion, CIV Ca loading increased FGF23 in normal and uremic rats, and renal α-Klotho is necessary to maintain the bioactivity of FGF23 as a phosphaturic factor.

Nur mit Berechtigung zugänglich

ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26(3):345–348CrossRef

Martin A, David V, Quarles LD (2012) Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 92:131–155CrossRefPubMedPubMedCentral

Antoniucci DM, Yamashita T, Portale AA (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91:3144–3149CrossRefPubMed

Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519–1524CrossRefPubMed

Arai-Nunota N, Mizobuchi M, Ogata H, Yamazaki-Nakazawa A, Kumata C, Kondo F, Hosaka N, Koiwa F, Kinugasa E, Shibata T, Akizawa T (2014) Intravenous phosphate loading increases fibroblast growth factor 23 in uremic rats. PLoS ONE 9:e91096CrossRefPubMedPubMedCentral

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro -OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408CrossRefPubMedPubMedCentral

Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552CrossRefPubMedPubMedCentral

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7:810–819CrossRefPubMed

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Group (2011) Fibroblast growth factor 23 and risks of mortality and end stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439CrossRefPubMedPubMedCentral

10.

Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles Q (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17(5):1305–1315CrossRefPubMed

11.

Yu X, Sabbagh Y, Davis SI, Demay MB, White KE (2005) Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating FGF23 concentrations. Bone 36:971–977CrossRefPubMed

12.

Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper HA, Hsieh JC, Slater SA, Hsieh G, Kaczmarska M, Jurutka PW, Kolek OI, Ghishan FK, Haussler MR (2007) 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 103:381–388CrossRefPubMed

13.

Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S (2010) Fibroblast growth factor 23 production in bone is directly regulated by 1α,25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 299:F1212–F1217CrossRefPubMed

14.

Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, Haussler CA, Jurutka PW (2012) The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 13:57–69CrossRefPubMedPubMedCentral

15.

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure:a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299(4):F882–F889CrossRefPubMed

16.

Lopez I, Rodriguez-Ortiz ME, Almaden Y, Guerrero F, de Oca AM, Pineda C, Shalhoub V, Rodriguez M, Aguilera-Tejero E (2011) Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 80:475–482CrossRefPubMed

17.

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088–F1095CrossRefPubMed

18.

Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez-Moreno JM, Ramirez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, Rodriguez M, Felsenfeld A, Almaden Y (2012) Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23:1190–1197CrossRefPubMedPubMedCentral

19.

Gravesen E, Mace ML, Hofman-Bang J, Olgaard K, Lewin E (2014) Circulating FGF23 levels in response to acute changes in plasma Ca²⁺. Calcif Tissue Int 95(1):46–53CrossRefPubMed

20.

Katherine WP, Wang H, Elashoff R, Gales B, Jüppner H, Salusky IB (2014) Lack of FGF23 response to acute changes in serum calcium and PTH in humans. J Clin Endocrinol Metab 99(10):E1951–E1956CrossRef

21.

Nicholas SB, Yuan J, Aminzadeh A, Norris KC, Crum A, Vaziri ND (2012) Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy. Am J Transl Res 4:257–268PubMedPubMedCentral

22.

Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65(5):1943–1946CrossRefPubMed

23.

di Giuseppe R, Kühn T, Hirche F, Buijsse B, Dierkes J, Fritsche A, Kaaks R, Boeing H, Stangl GI, Weikert C (2015) Potential Predictors of plasma fibroblast growth factor 23 concentrations: cross-sectional analysis in the EPIC-Germany Study. PLoS ONE 10(7):e0133580CrossRefPubMedPubMedCentral

24.

Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18(10):2683–2688CrossRefPubMed

25.

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimentalkidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299(4):F882–F889CrossRef

26.

Quinn SJ, Thomsen AR, Pang JL, Kantham L, Bräuner-Osborne H, Pollak M, Goltzman D, Brown EM (2013) Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 304(3):E310–E320CrossRefPubMed

27.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123CrossRefPubMedPubMedCentral

28.

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774CrossRefPubMed

29.

Kuro-o M (2008) Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 19:239–245CrossRefPubMed

30.

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51CrossRefPubMed

31.

Potts JT, Kronenberg HM, Rossenbalatt M (1982) Parathyroid hormone: chemistry, biosynthesis and mode of action. Adv Protein Chem 35:323–396CrossRefPubMed

32.

Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD (2008) Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3(3):658–664CrossRefPubMedPubMedCentral

33.

Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT (2007) Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22(6):931–937CrossRefPubMed

34.

Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, Hasegawa H, Yamashita T, Nakatani K, Saito Y, Okamoto N, Kurumatani N, Namba N, Kitaoka T, Ozono K, Sakai T, Hataya H, Ichikawa S, Imel EA, Econs MJ, Nabeshima Y (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398(3):513–518CrossRefPubMedPubMedCentral

35.

Yokoyama K, Imura A, Ohkido I, Maruyama Y, Yamazaki Y, Hasegawa H, Urae J, Sekino H, Nabeshima Y, Hosoya T (2012) Serum soluble α-Klotho in hemodialysis patients. Clin Nephrol 77(5):347–351CrossRefPubMed

36.

Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, Iwamoto N, Kurumatani N, Iwano M, Nabeshima Y, Konishi N, Saito Y (2014) Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS ONE 9(1):e86301CrossRefPubMedPubMedCentral

37.

Takenaka T, Watanabe Y, Inoue T, Miyazaki T, Suzuki H (2013) Fibroblast growth factor 23 enhances renal klotho abundance. Pflugers Arch 465(7):935–943CrossRefPubMed

38.

Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C, Sales S, Farcomeni A, Mazzaferro S (2015) Soluble α-Klotho serum levels in chronic kidney disease. Int J Endocrinol 2015:872193CrossRefPubMedPubMedCentral

39.

Lindberg K, Amin R, Moe OW, Hu MC, Erben RG, Östman Wernerson A, Lanske B, Olauson H, Larsson TE (2014) The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 25(10):2169–2175CrossRefPubMedPubMedCentral

Titel: Effect of Continuous Intravenous Calcium Loading on Fibroblast Growth Factor 23 in Normal and Uremic Rats
verfasst von: Yasuto Shikida
Masahide Mizobuchi
Takashi Inoue
Toma Hamada
Hiroaki Ogata
Fumihiko Koiwa
Takanori Shibata
Publikationsdatum: 07.06.2018
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 4/2018
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-018-0440-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Melatonin Suppresses Estrogen Deficiency-Induced Osteoporosis and Promotes Osteoblastogenesis by Inactivating the NLRP3 Inflammasome

lncRNA HOTAIR Inhibits Mineralization in Osteoblastic Osteosarcoma Cells by Epigenetically Repressing ALPL

C-X-C Motif Chemokine 12 Enhances Lipopolysaccharide-Induced Osteoclastogenesis and Bone Resorption In Vivo

Periprosthetic Bone Mineral Density Around Uncemented Titanium Stems in the Second and Third Decade After Total Hip Arthroplasty: A DXA Study After 12, 17 and 21 Years

Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women